Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR MOUAFFAK ISSA
10 RUE ROSA PARKS, 94400 VITRY SUR SEINE
CDS MUNICIPAL DE SANTE MAURICE TENINE
15 R MARCEL ET GEORGETTE SEMBAT, 94500 CHAMPIGNY SUR MARNE
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2019
ObjectiveTo assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA).MethodsData were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. Randomized dose comparison between baricitinib doses of 2 mg and 4 mg used data from 4 studies and from the associated long‐term extension study. The data analysis set designated “All‐bari‐RA” included all baricitinib exposures at any dose.ResultsOverall, 3,492 RA patients received baricitinib (7,860 patient‐years of exposure). No imbalance compared to the placebo group was seen in the incidence of major adverse cardiovascular events (MACE) (incidence rates [IRs] of 0.5 per 100 patient‐years for placebo and 0.8 per 100 patient‐years for 4 mg baricitinib), arterial thrombotic events (ATE) (IRs of 0.5 per 100 patient‐years for placebo and 0.5 per 100 patient‐years for 4 mg baricitinib), or congestive heart failure (CHF) broad term (IRs of 4.3 per 100 patient‐years for placebo and 2.4 per 100 patient‐years for 4 mg baricitinib). Deep vein thrombosis (DVT)/pulmonary embolism (PE) were reported in 0 of 1,070 patients treated with placebo and 6 of 997 patients treated with 4 mg baricitinib during the placebo‐controlled period; these events were serious in 2 of 6 patients, while all 6 had risk factors and 1 patient developed DVT/PE after discontinuation of the study drug. In the 2 mg–4 mg‐extended data analysis set, IRs of DVT/PE were comparable between the doses across event types (IRs of 0.5 per 100 patient‐years in those receiving 2 mg baricitinib and 0.6 per 100 patient‐years in those receiving 4 mg baricitinib). In the All‐bari‐RA data analysis set, the rates were stable over time, with an IR of DVT/PE of 0.5 per 100 patient‐years.ConclusionIn RA clinical trials, no association was found between baricitinib treatment and the incidence of MACE, ATE, or CHF. With regard to incidence of DVT/PE, 6 events occurred in patients treated with 4 mg baricitinib, but no cases of DVT/PE were reported in the placebo group. During longer‐term evaluation, the incidence of DVT/PE was similar between the baricitinib dose groups, with consistent IR values over time, and this was similar to the rates previously reported in patients with RA.
Annals of the rheumatic diseases · 2020
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Advances in therapy · 2025 · Published Erratum
Taylor PC, Bieber T, Alten R, Witte T, et al.
Advances in therapy · 2023 · Published Erratum
Bieber T, Feist E, Irvine AD, Harigai M, et al.
RMD open · 2023 · Randomized Controlled Trial
Morand E, Smolen JS, Petri M, Tanaka Y, et al.
Advances in therapy · 2023 · Randomized Controlled Trial
Taylor PC, Bieber T, Alten R, Witte T, et al.
Advances in therapy · 2022 · Journal Article
Bieber T, Feist E, Irvine AD, Harigai M, et al.
Annals of the rheumatic diseases · 2022 · Journal Article
Taylor PC, Takeuchi T, Burmester GR, Durez P, et al.
RMD open · 2020 · Journal Article
Kay J, Harigai M, Rancourt J, Dickson C, et al.
Annals of the rheumatic diseases · 2020 · Journal Article
Winthrop KL, Harigai M, Genovese MC, Lindsey S, et al.
Arthritis care & research · 2020 · Clinical Trial, Phase III
Fleischmann R, Takeuchi T, Schiff M, Schlichting D, et al.
The Lancet. Rheumatology · 2020 · Journal Article
Genovese MC, Smolen JS, Takeuchi T, Burmester G, et al.
Modern rheumatology · 2020 · Clinical Trial, Phase II
Harigai M, Takeuchi T, Smolen JS, Winthrop KL, et al.
Annals of the rheumatic diseases · 2019 · Clinical Trial, Phase III
Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2019 · Journal Article
Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, et al.
Arthritis research & therapy · 2019 · Clinical Trial, Phase III
Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2018 · Journal Article
Tanaka Y, McInnes IB, Taylor PC, Byers NL, et al.
International journal of spine surgery · 2023 · Journal Article
Ghali A, Prabhakar G, Momtaz D, Ahmad F, et al.
Global spine journal · 2023 · Journal Article
Lenga P, Issa M, Krull L, Kiening K, et al.
Respiratory medicine case reports · 2023 · Case Reports
Nasreddine S, Issa M, Bacha ZA
PloS one · 2021 · Journal Article
Krueger J, Santinon F, Kazanova A, Issa ME, et al.
Scientific reports · 2020 · Journal Article
Cohen IV, Makunts T, Moumedjian T, Issa MA, et al.
Journal of the neurological sciences · 2023 · Journal Article
Issa M, Donaldson L, Margolin E
The American journal of managed care · 2006 · Journal Article
Issa MM, Fenter TC, Black L, Grogg AL, et al.
Therapeutic advances in musculoskeletal disease · 2022 · Journal Article
Issa MR, Naja AS, Bouji NZ, Sagherian BH
Strategies in trauma and limb reconstruction · 2022 · Journal Article
Naja AS, Bouji N, Eddine MN, Alfarii H, et al.
Journal of human genetics · 2019 · Journal Article
Abdel-Hamid MS, Issa MY, Elbendary HM, Abdel-Ghafar SF, et al.
The Journal of pathology · 1973 · Journal Article
Davies JD, Berry H, Bacon PA, Issa MA, et al.
Annals of the rheumatic diseases · 2019 · Clinical Trial, Phase III
Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, et al.
Radiology. Cardiothoracic imaging · 2019 · Case Reports
Winkler MA, Kapoor H, Elashery AR, Issa M, et al.
Therapeutic advances in musculoskeletal disease · 2022 · Journal Article
Issa MR, Naja AS, Bouji NZ, Sagherian BH
RMD open · 2023 · Randomized Controlled Trial
Morand E, Smolen JS, Petri M, Tanaka Y, et al.
Anais brasileiros de dermatologia · 2010 · Journal Article
Issa MC, Manela-Azulay M
Journal of shoulder and elbow surgery · 2024 · Journal Article
Reddy RP, Sabzevari S, Karimi A, Dadoo S, et al.
Mayo Clinic proceedings. Innovations, quality & outcomes · 2020 · Case Reports
Shadrin IY, Albitar HAH, Paim AC, Issa M, et al.
Clinical medicine & research · 2014 · Case Reports
Savcic-Kos RM, Mali P, Abraham A, Issa M, et al.
Le Journal medical libanais. The Lebanese medical journal · 2012 · Journal Article
Maalouf G, Bachour F, Issa M, Yazbeck P, et al.
Arthritis care & research · 2020 · Clinical Trial, Phase III
Fleischmann R, Takeuchi T, Schiff M, Schlichting D, et al.